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Objective:  SLE Responder Index (SRI) is a composite endpoint used in SLE trials.   This 
investigation examined the clinical trial elements that drive response measured by SRI.   
Methods:  Analyses are based on data from two phase 3 trials (n=2262) that evaluated 
the impact of an anti-BAFF antibody on disease activity using SRI-5 as primary endpoint 
(NCT01196091, NCT01205438).  
Results:  SRI-5 response rate at week 52 for all patients was 32.8%.  Non-response due 
to lack of SLEDAI improvement, concomitant medication non-compliance or dropout 
was 31%, 16.5% and 19.1%, respectively.  Non-response due to deterioration in BILAG or 
PGA after SLEDAI improvement, concomitant medication compliance and trial 
completion was 0.5%.  Disease activity in three SLEDAI organ systems was highly 
prevalent at baseline; mucocutaneous (90.6%), musculoskeletal (82.9%) and 
immunologic (71.6%).  Disease activity in each of the other organ systems was <11% of 
patients.  Four clinical manifestations were highly prevalent at baseline; arthritis (82.6%) 
rash (69.2%), alopecia (58.2%) and mucosal ulcer (32.5%).  The combined prevalence of 
renal, vascular and CNS disease at baseline was 17.6%; these patients had high SRI-5 
response rates. Adjustments to corticosteroids were allowed during the 1st 24 weeks.  
Increases in corticosteroids above 2.5 mg/d were observed in 16.2% of placebo patients 
over the first 24 weeks after randomization. 
3 
 
Conclusion: The primary drivers of SRI-5 response were SLEDAI improvement, 
concomitant medication adherence and trial completion.  Arthritis, rash, alopecia, and 
mucosal ulcer were the most prevalent clinical manifestations at baseline.  
Corticosteroid increases and rare, highly weighted disease manifestations in SLEDAI can 
confound the SRI signal.   
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Clinical trials in SLE require efficacy endpoints that can assess benefit across multiple 
organ systems.  Recently, several large trials have employed the SLE Responder Index 
(SRI) as a primary endpoint to assess efficacy (1-8).  SRI is a composite endpoint that 
measures clinical benefit across multiple organ systems, while ensuring that benefit is 
not accompanied by deterioration in other organ systems (9).  Benefit is measured by 
the SLE Disease Activity Index (SLEDAI) and must occur in the absence of clinical 
deterioration as measured by British Isles Lupus Assessment Group (BILAG) or 
Physician’s Global Assessment (PGA).  Patients must also comply with concomitant 
medication rules and complete the trial to be considered an SRI responder.  
The SRI has several useful characteristics, including use of validated disease activity 
instruments, the ability to ensure improvement without deterioration, and the 
acceptance by regulatory authorities as a registration endpoint (10).   
A key limitation of the SRI is that the SLEDAI reflects only complete resolution of disease 
manifestations and not partial resolution, which could be clinically meaningful.  In 
addition, it does not identify changes in specific disease manifestations.  
To understand the impact of a therapy on specific disease manifestations,one has to 
examine the individual components of the disease activity instruments used for SRI.  
SLEDAI measures the presence or absence of specific disease manifestations due to 
lupus disease activity in 9 organ systems.  The SLEDAI score is the sum score from each 
organ system and, in general, more severe organ system manifestations have greater 
numerical value.  Thus, improvement in SLEDAI does not distinguish between remission 
of a single severe disease manifestation and modest resolution of several milder disease 
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manifestations.  BILAG is a complex instrument that measures 97 items in 9 organ 
systems (11).  It can show some degree of incremental disease activity improvement and 
worsening, but does not distinguish multiple disease manifestations within one organ 
system.  PGA is a visual analog scale reflecting the physician’s overall assessment of 
disease activity and does not distinguish between organ systems.   
The data from previous phase 3 trials in SLE suggested that improvement in one disease 
activity instrument was rarely accompanied by worsening in another instrument (12). 
Since this could have broad implications for trial designs, the current report examines 
data from two international phase 3 SLE trials which used SRI-5 as the primary endpoint 
(5, 6) to better understand the factors that drive SRI.  Our hypothesis was that a better 
understanding of the SRI endpoint might provide insight for designing future SLE clinical 
trials.  
 
Patients and Methods 
The analyses are based on two large multinational phase 3 trials (n=2262) that were 
designed to evaluate the impact of an anti-BAFF antibody on SLE disease activity using 
SRI-5 (5,6).  All subjects provided written informed consent according to the declaration 
of Helsinki, and the design of the study was approved by local ethical committees and 
institutional review boards.  The current report explicitly makes no attempt to evaluate 
the efficacy of the therapeutic that was studied in the trials.  
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A detailed description of the methods for the clinical trials can be found in the primary 
publications. Protocols for the two trials were very similar.  Briefly, Trials 1 and 2 were 
52-week double-blind, placebo controlled studies with patients assigned 1:1:1 to 
placebo or one of two drug treatment arms.  Increases or decreases in corticosteroid 
dose were allowed from screening through the first 24 weeks.  Initiation or increase in 
dose of antimalarials or immunosuppressants was not permitted.  Key inclusion criteria 
included diagnosis of SLE according to ACR criteria, positive ANA titer ≥ 1:80, and SLEDAI 
score ≥6.  Patients with severe active lupus nephritis and/or CNS lupus were excluded, 
but stable, non-severe disease was allowed. 
The primary endpoint for both studies was the proportion of patients achieving an SLE 
Responder Index 5 (SRI-5) response at week 52, defined as ≥5 point improvement in 
SELENA-SLEDAI (SLEDAI) score, no new BILAG 2004 score of A or no more than one new 
BILAG B score, and no worsening (increase ≥0.3 points from baseline on a 3 point scale) 
in PGA.  SRI-5 responders had to meet all three clinical criteria, comply with the 
concomitant medication rules and complete the trial.  In Trial 1, patients that decreased 
antimalarial or immunosuppressant treatment were also considered non-responders.  As 
discussed in the original report (5), it was recognized that imputation of non-response 
for decreasing background medications may have created a false negative responder 
assignment.  
The current analyses included all patients in the analysis of baseline disease 
characteristics.  Analyses subsequent to randomization are confined to the placebo 
population, with exception of the primary endpoint analysis, where the combined 
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treatment groups provide additional information concerning the factors contributing to 
SRI-5 non-response.  Analyses related to stability of SRI-5 response over time were 
confined to weeks 24 and 52 as the primary endpoint was based on landmark analysis 
and corticosteroid dosing requirements were designed to be more stringent at these 
time points.   
All other time course analyses were based on patients with the disease manifestation at 
baseline and at least one post-baseline assessment.  These analyses were based on all 
observed data collected at each study visit.  There were no assumptions made about 
missing data, and analyses did not utilize data imputation for missing data.  The extent of 
missing data at any time point is largely reflected in the early termination rates which 
were comparable across treatment groups in both trials (Supplemental Figure 1).  The 
reasons for early termination were also similar across treatment groups.  Given the 
similar rates and reasons for early termination, and the retrospective nature of several 
analyses, it was concluded that it would be more conservative to use observed data, and 





Trials 1 and 2 randomized 379 and 376 patients to placebo, and 759 and 748 patients to 
the combined treatment arms, respectively.   
SRI-5: Reasons for Non-Response 
Examination of the contribution of the 3 disease activity instruments (SLEDAI, BILAG, 
PGA) on SRI-5 response status confirms that improvement in SLEDAI is a key driver of 
SRI response, while the disease activity instruments that measure deterioration have 
minimal incremental impact on the primary endpoint (Figure 1).   Failure to achieve ≥ 5 
point reduction in SLEDAI was observed in 29.6% and 35.1% of placebo, and 30.7% and 
30.1% of the combined treatment groups in Trial 1 and Trial 2, respectively after 
accounting for concomitant medication rules and premature discontinuation.  In 
contrast, 0.6% (7/1138, Trial 1) and 0.4% (4/1124, Trial 2) of patients that completed the 
trials failed to achieve responder status due to deterioration by BILAG or PGA after 
achieving ≥ 5 point reduction in SLEDAI and complying with concomitant medication 
rules.   
Violation of concomitant medication rules and premature discontinuation had a 
substantial impact on SRI-5 rates.  Non-response due to failure to comply with 
concomitant medication rules was observed in 19.8% and 17.0% of placebo, and 16.7% 
and 14.3% of the combined treatment groups in Trial 1 and Trial 2, respectively. Failure 
to complete the 52-week trial after complying with conmed rules was observed in 20.1% 
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and 20.2% of placebo, and 18.8% and 18.4% of the combined treatment groups in in 
Trial 1 and Trial 2, respectively.  
SRI-5: Stability of Response over Time  
Most of the improvement in SRI-5 was observed by 24 weeks, and this proportion 
remained relatively stable for the remainder of the trial.  We examined the stability of 
the SRI-5 response between weeks 24 and 52 by evaluating the proportion of placebo-
treated patients who changed response status between week 24 and week 52.  In the 
placebo arm, 17.4% and 13.2% of non-responders at week 24 achieved SRI-5 at week 52 
in Trials 1 and 2, respectively (Supplementary Figure 2).  The proportion of placebo 
patients that deteriorated from week 24 (responder) to week 52 (non-responder) was 
30.8% and 29.1% of week 24 responders in Trials 1 and 2, respectively.  Thus, a 
substantial proportion of placebo patients change response status between weeks 24 
and week 52.   
Impact of High Prevalence Disease Manifestations on SRI 
The observation that SLEDAI is the dominant disease activity instrument driving the SRI 
endpoint prompted further investigation into individual SLEDAI organ systems and 
disease manifestations.  Three SLEDAI organ systems dominated baseline disease 
activity.  Disease activity in mucocutaneous, musculoskeletal and immunologic organ 
systems were present in over 70% of the patients, while disease activity in the other 6 
organ systems was present in fewer than 12% of the patients (Figure 2A and 2C).   
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We next examined the baseline prevalence of specific manifestations in the highly 
prevalent organ systems.   Arthritis was the most common manifestation, present in 81% 
and 84.3% of patients in Trial 1 and 2, respectively, while myositis was rare, present in 
only 1.2% of all patients.  The mucocutaneous organ system is comprised of 3 
manifestations, rash, alopecia and oral ulcers.  The baseline prevalence of rash was 71% 
and 67.4%, alopecia 61% and 55.4%, and mucosal ulcer 35.1% and 30% in Trials 1 and 2, 
respectively (Figure 2B and 2D).   
These analyses revealed that the majority of clinical disease activity at baseline 
consisted of 4 SLE disease manifestations, arthritis, rash, alopecia and mucosal ulcers.  In 
total, 98.6% (2231/2262) of patients had mucocutaneous and/or musculoskeletal organ 
system disease at baseline, while 95.9% (2170/2262) had rash and/or arthritis at 
baseline.  
Response rates for the 4 prevalent disease manifestations (present at baseline, negative 
at follow-up visit) were analyzed using the observed data (Figure 3).  Mucosal ulcer had 
the highest response rate over time while alopecia had the lowest response rate.  
Arthritis and rash response rates were intermediate between mucosal ulcer and 
alopecia.  Week 52 placebo response rates for each specific disease manifestation were 
mucosal ulcers (85.4%, 74.7%), rash (47.8%, 54.3%), arthritis (58.4%, 66.5%) and 





Impact of Low Prevalence Disease Manifestations on SRI 
Three of the 6 organ systems with low prevalence merited attention as they have high 
point values in SLEDAI.   Vascular and CNS domains assign 8 points per disease 
manifestation, so remission of a single manifestation provides all the clinical benefit 
needed to achieve SRI-5.  Vascular organ system disease was present in 7.6% and 7.2%, 
while CNS organ system disease was present in 1.3% and 2% of patients in Trials 1 and 2, 
respectively.  (Figure 4, Panels A and C).  CNS disease manifestations included Visual 
Disturbance (n=12, n=20), Lupus Headache (n=2, n=3) and Organic Brain Syndrome (n=1, 
n=0) in Trials 1 and 2, respectively.  The renal domain assigns 4 points per disease 
manifestation and was present in 10.4% and 9% of patients in Trials 1 and 2, 
respectively.  Renal disease manifestations included Pyuria (n=66, n=53), Hematuria 
(n=48, n=46), Proteinuria (n=39, n=35), and Urinary Casts (n=1, n=6) in Trials 1 and 2, 
respectively  
While the proportion of patients with renal, vascular or CNS organ system involvement 
at baseline was less than 11% for any single organ system, most of these patients (93.2% 
and 93.8% in Trials 1and 2, respectively) had only one of these 3 organ systems active at 
baseline.  Thus, the proportion of patients with high value, low prevalence organ 
systems active at baseline approximated the total number of patients with renal, 
vascular and CNS disease at baseline, with 18.1% and 17.2% of patients active in Trials 1 
and 2, respectively.  The Week 52 SRI-5 response rate for placebo patients with CNS, 
vascular, or renal involvement at baseline ranged from 45% to 67% in the two trials 
(Figure 4, panels B and D).   
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The remaining 3 organ systems with low prevalence at baseline assign 1-2 pts per 
manifestation and were not further evaluated.   
 
Concomitant Medications  
Most patients were taking SLE-related medications at baseline, including corticosteroids 
(78.3%, 74.1%), immunosuppressants (43.8%, 39.9%) and anti-malarials (63.7%, 70.3%) 
in Trials 1 and 2, respectively.  To better understand the impact corticosteroids, we 
analyzed the cumulative proportion of placebo patients with an increase in average daily 
prednisone dose of ≥ 2.5 mg/day between visits.  Less than 20% of placebo patients met 
this threshold for increase in prednisone over the first 24 weeks. (Figure 5).  Placebo 
patients with increased corticosteroids were evident throughout the trials. 
(Supplementary Figure 3).  
 As increases in prednisone may reflect clinical deterioration, we evaluated SRI-5 
response in patients with increases in prednisone during the first 24 weeks.  SRI-5 
response at week 24 in placebo patients with increased prednisone dose was 26.1% and 
25% in Trials 1 and 2, respectively (Figure 6).   
Few patients discontinued corticosteroids during the trial(3.1% (9/294) and 2.2% (6/274) 
discontinued corticosteroids in placebo in Trial 1 and 2, respectively.  Increases in 
immunosupressants and anti-malarials were were also infrequent in the trials(4.5% 
(17/379) and 5.6% (21/376) increased immunosupressants or anti-malarials in placebo 




This study examined two large phase 3 SLE trials to evaluate factors that impact SRI 
response status in SLE trials.  The analyses demonstrate that improvement in SLEDAI, 
concomitant medication rules, and early termination are the parameters that most 
strongly influence response status in SRI-5- based SLE trials. BILAG and PGA are valuable 
instruments, but when used to counter response status in patients who have already 
met improvement criteria, they have negligible incremental impact on response status.  
Four clinical manifestations- rash, arthritis, alopecia and mucosal ulcer – are highly 
prevalent at baseline while all other clinical manifestations are much less prevalent.  
These 4 clinical manifestations, along with anti-dsDNA and low complement, provide 
most of the opportunity for improvement in SLEDAI.   
The analyses showing that BILAG and PGA contribute minimal additional incremental 
information to SRI reflect the order in which the terms are analyzed, and not the 
individual value of BILAG and PGA.  The principle behind SRI – improvement without 
worsening – influences the order of the calculations to determine responders and non-
responders.  The hierarchy logically begins with identifying those patients that could 
never achieve responder status due to failure to complete the trial or violation of the 
concomitant medication rules.  Improvement in SLEDAI is the next gate, followed by 
BILAG and PGA to identify patients with worsening disease despite improvement in 
SLEDAI.    This was a meaningful theoretical construct since the SLEDAI does not increase 
in score when a sign or symptom that was present at baseline worsens. The current data 
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confirms that improvement by SLEDAI is rarely accompanied by deterioration by BILAG 
or PGA. 
Individually, SLEDAI, BILAG and PGA all provide value as they allow one to estimate the 
proportion of patients that improved, and the proportion that worsened, over the 
course of a trial.  However, for clinical trials that are intended to study new therapeutics 
in SLE patients with common non- major organ threatening disease manifestations, a 
simple, dichotomous improvement in SLEDAI score, coupled with successful trial 
completion and medication stability, may provide a simple and potentially more clinically 
relevant approach to assess outcome.  Clinical trials will continue to require an 
assessment of worsening/deterioration, including both safety and flare analyses. 
Evaluation of therapeutics for infrequent SLE disease manifestations will likely require 
trial designs that enrich for the population of interest. 
The original derivation of the SRI by Furie et al. (9) has had a major impact on SLE drug 
development, having since been deployed as the primary endpoint in many clinical 
trials.  Interestingly, there is an important difference in definition of non-response 
between the original SRI and the SRI endpoint used in current trials. Because there was 
unlimited flexibility with background medications in the trial used to derive SRI, the 
original SRI did not account for increases in concomitant medications. Thus, the original 
SRI identified a number of patients with BILAG or PGA worsening, despite SLEDAI 
improvement.  In its current iteration, the SRI captures many of these patients with 
worsening disease by the increase in therapies used to treat the disease activity. 
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The prevalence and response patterns of the 4 most common clinical manifestations 
illustrate how they impact SRI.  Arthritis and rash were the most prevalent 
manifestations, as over 95% of patients had one or both of these manifestations.  
Placebo response rates for rash, arthritis and alopecia are in a range where an effective 
treatment has the potential to show benefit over and above standard therapy.  In 
contrast, placebo response rates for mucosal ulcer were high, approaching 80% at 52 
weeks.  This high placebo rate in mucosal ulcer could potentially limit the ability to 
detect a treatment benefit for a drug that was effective for this manifestation.  It is 
noted that these response rates would be lower when non-response is imputed for early 
termination and violation of concomitant medication rules. 
The SLEDAI point value for arthritis, rash, alopecia and mucosal ulcers is not sufficient in 
isolation to qualify patients for trials that require SLEDAI ≥ 6 for enrollment.  Thus, these 
manifestations represent the most frequent manifestations in the larger constellation of 
disease activity present in the clinical trial population.   
We examined the 6 SLEDAI organ systems with low prevalence at baseline to see how 
activity in those systems at baseline impacted the SRI response.  Less than 11% of 
patients had disease activity in each of these organ systems at baseline; therefore, 
analysis of response in these organ systems is likely to be underpowered for treatment 
benefit, even in large phase 3 trials.  However, the low prevalence organ systems with 
high point value in SLEDAI are of interest, since remission in a single manifestation 
within these organ systems can provide most or all of the SLEDAI improvement needed 
to achieve SRI response.  There was little overlap between patients with CNS, vascular, 
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or renal disease activity at baseline.  Thus, cumulatively they represented 17-18% of the 
patients in the trial.  Placebo patients with disease activity in these 3 organ systems at 
baseline had SRI-5 response rates that were greater than the ITT placebo SRI-5 response 
rate.  Thus, these high value organ systems, which clearly reflect important and serious 
manifestations of SLE, have the potential to impact the trial outcome despite their 
relatively low prevalence at baseline. 
The time course of the SRI response curve over time in these trials was similar to that 
observed in most recent 52 week SLE trials, where the change from baseline is greatest 
over the first 6 months, followed by a relatively stable proportion of responders in the 
second half of the trial (1, 2, 5, 6, 8).  It was interesting to observe that many placebo 
patients changed response status between week 24 and week 52, from SRI responder to 
non-responder, and vice versa.  While response at week 24 was maintained to week 52, 
response at earlier timepoints, i.e. 6 months, may more accurately reflect improvement 
in baseline disease activity.  
Many SLE trials have allowed increases in corticosteroids after randomization.  Our 
analyses reveal that less than 20% of patients increased their average daily prednisone 
dose by more than 2.5 mg/day between visits during the first 24 weeks, a period where 
the protocol permitted increases in prednisone.  These data suggest it may be feasible 
to completely restrict increases in corticosteroid doses after randomization in an SLE 
population with non-organ threatening disease manifestations.  Patients with 
exacerbating disease activity could still receive rescue therapy, but they would be 
considered non-responders in the analysis.   
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Increases in corticosteroids doses may reflect clinical deterioration.   Thus, it was not 
surprising that SRI-5 response rates at Week 24 were lower in patients receiving 
increases in corticosteroids compared to patients with stable prednisone doses.  
However, approximately 25% of placebo patients receiving an increase in corticosteroid 
doses during the first 24 weeks did achieve SRI-5 response at Week 24, consistent with 
the possibility that increases in corticosteroid dose may have contributed to the SRI-5 
response rate at week 24 in placebo patients that otherwise may not have achieved 
responder status due to clinical deterioration. 
It’s not possible to generalize the observations reported here to other SRI-driven SLE 
trials without repeating the specific analyses.  However, there are data indicating that at 
least some of the observations are likely to be qualitatively similar across trials.  For 
example, in the belimumab phase 3 SLE trials, the proportion of patients with ≥ 4 point 
reduction in SLEDAI that failed to achieve SRI-4 due to worsening of BILAG or PGA 
ranged from 0.3% to 2.2% after accounting for dropouts and rescue medication (12).  An 
independent study also confirmed that SLEDAI does not conceal worsening in other 
organ systems when there is overall improvement (13).  Disease involvement by organ 
system in the belimumab phase 3 trials was similar to the current observations, where 
mucocutaneous, musculoskeletal and immunological organ domains were the most 
prevalent SLEDAI organ domains at baseline, and the other 6 organ domains were much 
less prevalent (14).  The concomitant medication analyses reported here are less readily 
generalized to other SRI based trials, as the rules governing changes in concomitant 
medications, especially corticosteroids, are often unique to each trial.   
18 
 
In conclusion, the analyses identify the efficacy variables that have the greatest impact 
on SRI response status, as well as the variables that may confound assessment of 
treatment effect.  The results show that SLEDAI, concomitant medication rules and trial 
completion are the major drivers of SRI responder status.   They also show that a 
relatively finite number of disease manifestations in SLEDAI drive SRI outcomes.  Finally, 
the analyses characterize variables that potentially contribute noise in the trial, including 
corticosteroids and rare, highly weighted disease manifestations within SLEDAI.   
 
Key Messages 
 SLE Responder Index endpoint is determined by SLEDAI, concomitant 
medications and trial completion. 
 Arthritis and mucocutaneous manifestations were prevalent at baseline; other SLE 
manifestations were much less prevalent.  
 Corticosteroids and rare, highly-weighted SLEDAI disease manifestations can 
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Figure 1:  SLE Responder Index Endpoint is Driven by SLEDAI, Concomitant Medication 
Rules and Trial Completion 
Proportion of patients that met SRI-5 response criteria (A,C) and reasons for non-
response (B, D) in Trial 1 (A,B) and Trial 2 (C,D).   Reasons for non-response in Panels B 
and D were determined sequentially in the order shown from left to right.  The analyses 
are based on the ITT population which included all patients that participated in trial and 
received at least one dose of study drug.  For Trial 1, n=379 in placebo and n=759 in the 
combined treatment arms.  For Trial 2, n=376 in placebo and n=748 in the combined 
treatment arms.  The combined treatment arms included a q2wk and a q4wk dose arm 
in each trial. 
Figure 2:  Disease Activity at Baseline by SLEDAI Organ System and Disease 
Manifestation  
Proportion of patients with active disease manifestations at baseline by SLEDAI organ 
system (A ,C) and specific SLEDAI disease manifestation (B, D) for the combined 
treatment populations in Trial 1 (A,B) and Trial 2 (C,D).  Individual SLEDAI disease 
manifestations in Panels B and D are shown for the 3 highly prevalent organ systems 
(mucocutaneous, musculoskeletal and immunologic) and are color coded to their organ 
system in Panels A and C.  Percentages are calculated from the baseline values for the 
combined ITT population (placebo plus both dose arms) prior to first administration of 




Figure 3:  Response Rates for High Prevalence SLEDAI Disease Manifestations in 
Placebo Patients  
Response rate over time in placebo population for the 4 high prevalence SLEDAI clinical 
disease manifestations (A: Arthritis; B: Rash; C: Alopecia; D: Mucosal Ulcer).  Each 
analysis represents the sub-population of placebo patients that had the disease 
manifestation at baseline by SLEDAI.  Patients were considered responders if disease 
manifestation had resolved at the indicated visit.     At baseline, the analysis include 
n=306 and n=313 (arthritis), n=270 and n=245 (rash), n=235 and n=209 (alopecia), 
n=135 and n=107 (mucosal ulcer) for Trials 1 and 2, respectively.  Analyses were 
conducted using observed data at each visit with no imputation for missing data or drop-
outs. 
Figure 4:  Impact of Rare, Highly-Weighted SLEDAI Disease Manifestations on the SLE 
Responder Index Endpoint.   
Baseline prevalence of renal, vascular and CNS disease as measured by SLEDAI organ 
system in ITT population (A, C) and SRI-5 response rate in placebo patients with renal, 
vascular and CNS disease at week 52 (B, D) in Trial 1 (A,B) and Trial 2 (C,D).  Renal, 
vascular and CNS organ systems were investigated due to high SLEDAI point value when 
calculating SRI-5 response rates.  Few patients had activity in more than one of these 
organ systems at baseline, as indicated in Panels A and C.  SRI-5 response rates in 
placebo patients with renal, vascular or CNS disease were greater than the response rate 
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in the ITT populations.  SRI-5 response rates are confined to placebo and based on n= 
379 and n=376 (ITT), n=42 and n=30 (renal), n= 30 and n=26 (vascular) and n=6 and n=7 
(CNS) in Trials 1 and 2, respectively. 
Figure 5:  Placebo Patients that Increased Corticosteroids After Randomization 
Cumulative proportion of placebo patients with increase in average daily prednisone use 
of ≥ 2.5 mg/day between visits during the first 24 weeks in Trial 1 and Trial 2.  Analysis 
was limited to placebo patients during the first 24 weeks when increases in steroids 
were allowed.  The number of patients at randomization was n=379 and n=376 in Trials 1 
and 2, respectively. 
 
Figure 6:  Impact of Increases in Corticosteroids on SLE Responder Index Endpoint in 
the Placebo Population 
SRI-5 response rate at week 24 in the subset of placebo patients that were taking 
corticosteroids at baseline in Trial 1 (A) and Trial 2 (B).  Placebo patients were separated 
into two populations for the analysis; patients with stable corticosteroids that did not 
increase more than 2.5 mg/day between visits, and patients that had protocol permitted 
increases in corticosteroids, defined as ≥ 2.5 mg/day increase in average daily 
prednisone use between visits during the first 24 weeks.  Number of patients in each 
analysis is defined in the legend as (number achieving SRI-5 at week 24/total number of 




Supplementary Figure 1:  Early Termination Rates In the Trials  
Early termination rates by treatment group in Trial 1 (A) and Trial 2(B).  Early termination 
rates were similar across treatment groups and across trials.  The comparability of these 
rates mitigates the possibility that analyses based on observed data were biased due to 
differences in early termination rates.  
 
Supplementary Figure 2:  Placebo Patients that Change SLE Responder Index-Response 
Status Between Week 24 and Week 52 
Proportion of placebo patients that change SRI-5 response status between weeks 24 and 
52 in Trial 1 (A) and Trial 2 (B).  Patients with gain in SRI-5 were non-responders at week 
24 and responders at week 52.  Patients with loss of SRI-5 were responders at week 24 
and non-responders at week 52.  Percentages are based on the total number of patients 
with response or non-response at week 24 that could change response status at week 
52.  Values at each time point are based on observed data.  NRI (non-responder 
imputation) reflects SRI-5 response rate at week 52 utilizing the prospectively defined 
imputation rules  for non-responders from the primary analysis.  
 
Supplementary Figure 3:  Placebo Patients that Increased Corticosteroids at Each Visit, 
Non-Cumulative Analysis 
Proportion of placebo patients with an increase in average daily prednisone dose 
compared to baseline at each individual visit in Trial 1 and Trial 2.  Increase in 
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corticosteroids is defined as change from baseline > 2.5 mg per day.  The number of 
patients at randomization was n=379 and n=376 in Trials 1 and 2, respectively, and 
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